2. UroToday Home
  3. Journal
  4. Everyday Urologyâ„¢ – Oncology Insights
  5. Articles

AUA 2011 - SPU: The long-term collateral damage of curing pediatric genito-urinary cancers - Session Highlights

 

WASHINGTON, DC USA (UroToday.com) - Dr. Jeff Dome presented data demonstrating the marked improvements in survival with Wilms’ tumor, rhabdomyosarcomas of the GU tract, as well as testicular cancers.

AUA 2011 - SPU: Renal outcomes in children treated with Wilm's Tumor - Session Highlights

AUA 2011 - Studies link quality of sleep to erectile dysfunction, other urologic conditions - Press Release

WASHINGTON, DC USA (UroToday.com) - May 14, 2011 - Patient access to care, the role of telemedicine and quality issues are all key tenets in today’s healthcare debate, and five new studies being presented during the 2011 Annual Meeting of the American Urological Association will provide valuable data that will contribute to the national discussion.

AUA 2011 - Staggering one in three women live with stress urinary incontinence, fear of stigma limits discussion with doctor - Press Release

WASHINGTON, DC USA (UroToday.com) - May 13, 2011 

New Monograph Unveiled at American Urological Association Annual Meeting Underscores Prevalence of Condition, Encourages Open Dialogue

EAU 2011 - Does biochemical progression after radical prostatectomy and adjuvant radiotherapy for locally advanced prostate cancer invariably impact cancer-specific mortality? - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This group's objective was to examine the prognosis of patients who experienced biochemical progression (BCR) after adjuvant radiotherapy (aRT) for prostate cancer (CaP).

EAU 2011 - A preoperative serum biomarker panel to identify patients with prostate cancer at high risk of biochemical recurrence following radical prostatectomy - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - The intent of this study was to improve upon existing nomograms to predict the likelihood of prostate cancer (CaP) recurrence following radical prostatectomy by integrating biomarkers.

EAU 2011 - Adjuvant radiotherapy leads to superior biochemical recurrence free survival compared to early salvage radiotherapy in patients with locally advanced prostate cancer: Results of a matched-controlled multi-institutional analysis - Session Highli

VIENNA, AUSTRIA (UroToday.com) - This was a collaborative study among European institutions. Since only about one-third of prostate cancer patients with adverse pathology on radical prostatectomy (RP) benefit from adjuvant radiotherapy (aRT), many urologists choose to monitor sensitive PSA tests and administer early salvage radiotherapy (eSRT) instead.

EAU 2011 - Androstenedione is the most efficient precursor of intraprostatic testosterone production in primary human prostate cancer tissue - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - Even with castrate levels of testosterone, the androgen receptor is activated in prostate cancer (CaP) due to several mechanisms.

EAU 2011 - Health-related quality of life after salvage high intensity focused ultrasound treatment (HIFU) for locally radiorecurrent prostate cancer - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - The study goal was to evaluate health related quality of life (HRQOL) after salvage high intensity focused ultrasound (HIFU) for locally radio-recurrent prostate cancer (CaP).

EAU 2011 - Prostate cancer associated up-regulation of AMACR, EZH2 and PSMA correlates with diminished expression of specific microRNAs - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - MicroRNAs (miRNAs) are small pieces of non-coding RNA that were historically thought to have no significant function.

EAU 2011 - Serum levels of pro-inflammatory cytokines immediately increase two days after application of docetaxel in patients with castration-resistant prostate cancer and correlate with apoptosis and clinical response - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This group sought to further understand the balance of inflammatory and anti-tumoral immune responses in advanced prostate cancer (CaP).

EAU 2011 - Carbon footprint of laparoscopy in the United States - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This group from Memorial Sloan-Kettering Cancer Center evaluated carbon dioxide, the principal gas used in laparoscopic procedures for insufflation.

EAU 2011 - A meta-analysis comparing complication and positive surgical margin rates of 110,016 patients undergoing open retropubic, laparoscopic, and robotic-assisted radical prostatectomy - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This study was a literature review of articles published between 2002 and 2008 to assess and compare positive surgical margin and complication rates for open retropubic, laparoscopic, and robotic radical prostatectomy.

EAU 2011 - A multi-institutional study of 3794 patients undergoing robotic-assisted laparoscopic radical prostatectomy shows the learning curve is not as short as previously thought - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This group of investigators sought to define the learning curve for robotic assisted laparoscopic radical prostatectomy (RALP) with regards to positive surgical margin (PSM) rate and operative time (OT).

EAU 2011 - Differences in biochemical recurrence rate after focal and extensive positive surgical margins following radical prostatectomy - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - Level one evidence exists supporting the use of adjuvant radiotherapy following radical prostatectomy (RP) for patients with positive surgical margins (PSMs).

EAU 2011 - Pathologic stage at prostatectomy over time: Has there been a trend toward intervention for localized disease in the robotic era? - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - The goal of this study was to assess trends in pathologic stage for patients treated by radical prostatectomy between 1990 and 2010.

EAU 2011 - Radical prostatectomy in men with continuous oral aspirin medication: Revisiting old paradigm? - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - These investigators explored the issue of anticoagulation with aspirin and potential complications in patients undergoing radical prostatectomy (RP) for prostate cancer (CaP).

EAU 2011 - Clinical benefit of cabazitaxel plus prednisone in the TROPIC trial in men with metastatic castration resistant prostate cancer (mCRPC) who progressed after docetaxel-based treatment - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This study assessed patients with metastatic castration-resistant prostate cancer (mCRPC) who participated in the TROPIC trial, for clinical benefit and patient recorded pain assessment.

EAU 2011 - Clinical utility of PCA3 urine assay in Japanese men undergoing prostate biopsy - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - Ethnic and resultant genetic differences may mean that the performance of a diagnostic or prognostic assay in one country may not have the same results in another country.

EAU 2011 - Deregulation of miR339 in prostate cancer and metastases - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - MicroRNAs (miRNAs) are small pieces of non-coding RNA that were historically thought to have no significant function.

EAU 2011 - Long-term efficacy results from the phase 1-2 study of MDV3100 in pre- and post-docetaxel advanced prostate cancer - Session Highlights

VIENNA, AUSTRIA (UroToday.com) - This study provided an evaluation of MDV3100, a novel androgen receptor (AR) antagonist with activity against prostate cancer (CaP) over-expressing AR.
Page 584 of 588